Neoadjuvant chemotherapy (NACT) use in triple-negative breast cancer (TNBC) increased from 19.1% to 56.4% between 2010 and 2021, with pathologic complete response (pCR) rates rising from 19.6% to ...

A new study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer (TNBC) to develop resistance to therapy. Researchers at Baylor College of Medicine showed ...

Besides Ascent-04, Gilead expects a readout by June from the phase 3 Ascent-03 trial pitting Trodelvy against chemo in first-line, PD-L1-negative metastatic TNBC. The Ascent-05 study is testing ...

AstraZeneca’s first-in-class pan-AKT inhibitor Truqap was unable to improve overall survival (OS) in a phase 3 trial in triple-negative breast cancer (TNBC), denting the prospects of the new drug.

Merck & Co has claimed EU approval for Keytruda in triple-negative breast cancer (TNBC), a particularly hard-to-treat form of the disease. The European Commission has cleared Keytruda ...

The survival data for the Bria-IMT regimen + immune check point inhibitor in the triple negative breast cancer (TNBC), characterized by the absence of estrogen (ER), progesterone (PR) and human ...

Trodelvy + Keytruda improved progression-free survival over chemo + Keytruda in PD-L1+ metastatic TNBC. No new safety signals reported in ASCENT-04; overall survival trends will be tracked with ...

A new study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer (TNBC) to develop resistance to therapy. Standard-of-care treatment for TNBC includes ...